Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-α activation

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2384-2393

  Lee, Eun Jung ^a   Han, Jeong Eun ^b   Woo, Moon Sook ^a   Shin, Jin A ^a   Park, Eun Mi ^a   Kang, Jihee Lee ^a   Moon, Pyong Gon ^c   Baek, Moon Chang ^c   Son, Woo Sung ^d   Ko, Young Tag ^b   Choi, Ji Woong ^b   Kim, Hee Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Gachon University   (South Korea)

^c Kyungpook National University   (South Korea)

^d CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTROPHIL COLLAGENASE; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MMP8 PROTEIN, MOUSE; NERVE PROTEIN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL ACTIVATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOKINE RELEASE; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN PHOSPHORYLATION; SEPSIS; UPREGULATION; ANIMAL; BRAIN DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOXICITY;

ADAM PROTEINS; ANIMALS; BRAIN; BRAIN DISEASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED ICR; MICROGLIA; NERVE TISSUE PROTEINS; NF-KAPPA B; PHOSPHORYLATION; SEPSIS; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907021020     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303240     Document Type: Article

References (56)

1. Agrawal, S. M., L. Lau, and V. W. Yong. 2008. MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19: 42-51.
2. Verslegers, M., K. Lemmens, I. Van Hove, and L. Moons. 2013. Matrix metalloproteinase-2 and-9 as promising benefactors in development, plasticity and repair of the nervous system. Prog. Neurobiol. 105: 60-78.
3. Bahia, M. S., and O. Silakari. 2010. Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders. Chem. Biol. Drug Des. 75: 415-443.
4. Hansmann, F., V. Herder, A. Kalkuhl, V. Haist, N. Zhang, D. Schaudien, U. Deschl, W. Baumgärtner, and R. Ulrich. 2012. Matrix metalloproteinase-12 deficiency ameliorates the clinical course and demyelination in Theiler's murine encephalomyelitis. Acta Neuropathol. 124: 127-142.
5. Morancho, A., A. Rosell, L. García-Bonilla, and J. Montaner. 2010. Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann. N. Y. Acad. Sci. 1207: 123-133.
6. Rosenberg, G. A. 2009. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 8: 205-216.
7. Zhang, H., M. Chang, C. N. Hansen, D. M. Basso, and L. J. Noble-Haeusslein. 2011. Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 8: 206-220.
8. Yang, Y., J. F. Thompson, S. Taheri, V. M. Salayandia, T. A. McAvoy, J. W. Hill, Y. Yang, E. Y. Estrada, and G. A. Rosenberg. 2013. Early inhibition of MMP activity in ischemic rat brain promotes expression of tight junction proteins and angiogenesis during recovery. J. Cereb. Blood Flow Metab. 33: 1104-1114.
9. Lee, E. J., M. S. Woo, P. G. Moon, M. C. Baek, I. Y. Choi, W. K. Kim, E. Junn, and H. S. Kim. 2010. α-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of proteaseactivated receptor-1. J. Immunol. 185: 615-623.
10. Woo, M. S., J. S. Park, I. Y. Choi, W. K. Kim, and H. S. Kim. 2008. Inhibition of MMP-3 or-9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J. Neurochem. 106: 770-780.
11. Dejonckheere, E., R. E. Vandenbroucke, and C. Libert. 2011. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev. 22: 73-81.
12. Schubert-Unkmeir, A., C. Konrad, H. Slanina, F. Czapek, S. Hebling, and M. Frosch. 2010. Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: a role forMMP-8. PLoSPathog. 6: e1000874.
13. Folgueras, A. R., A. Fueyo, O. García-Suárez, J. Cox, A. Astudillo, P. Tortorella, C. Campestre, A. Gutiérrez-Fernández, M. Fanjul-Fernández, C. J. Pennington, et al. 2008. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J. Biol. Chem. 283: 9465-9474.
14. Light, M., K. H. Minor, P. DeWitt, K. H. Jasper, and S. J. Davies. 2012. Multiplex array proteomics detects increased MMP-8 in CSF after spinal cord injury. J. Neuroinflammation 9: 122.
15. Bocchini, V., R. Mazzolla, R. Barluzzi, E. Blasi, P. Sick, and H. Kettenmann. 1992. An immortalized cell line expresses properties of activated microglial cells. J. Neurosci. Res. 31: 616-621.
16. Cheepsunthorn, P., L. Radov, S. Menzies, J. Reid, and J. R. Connor. 2001. Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia 35: 53-62.
17. Park, J. S., E. M. Park, D. H. Kim, K. Jung, J. S. Jung, E. J. Lee, J. W. Hyun, J. L. Kang, and H. S. Kim. 2009. Anti-inflammatory mechanism of ginseng saponins in activated microglia. J. Neuroimmunol. 209: 40-49.
18. Lee, K. M., H. S. Kang, C. H. Yun, and H. S. Kwak. 2012. Potential in vitro protective effect of quercetin, catechin, caffeic acid and phytic acid against ethanol-induced oxidative stress in SK-Hep-1 cells. Biomol. Ther. (Seoul) 20: 492-498.
19. Woo, M. S., P. G. Jang, J. S. Park, W. K. Kim, T. H. Joh, and H. S. Kim. 2003. Selective modulation of lipopolysaccharide-stimulated cytokine expression and mitogen-activated protein kinase pathways by dibutyryl-cAMP in BV2 microglial cells. Brain Res. Mol. Brain Res. 113: 86-96.
20. Trott, O., and A. J. Olson. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31: 455-461.
21. Bolton, E. E., Y. Wang, P. A. Thiessen, and S. H. Bryant. 2008. Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities. Annu. Rep. Comput. Chem. 4: 217-241.
22. Pettersen, E. F., T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, and T. E. Ferrin. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25: 1605-1612.
23. Case, D. A., T. E. Cheatham, III, T. Darden, H. Gohlke, R. Luo, K. M. Merz, Jr., A. Onufriev, C. Simmerling, B. Wang, and R. J. Woods. 2005. The Amber biomolecular simulation programs. J. Comput. Chem. 26: 1668-1688.
24. Pearlman, D. A., D. A. Case, J. W. Caldwell, W. S. Ross, T. E. Cheatham, S. DeBolt, D. Ferguson, G. Seibel, and P. Kollman. 1995. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput. Phys. Commun. 91: 1-41.
25. Ewing, T. J., S. Makino, A. G. Skillman, and I. D. Kuntz. 2001. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des. 15: 411-428.
26. Kuntz, I. D., J. M. Blaney, S. J. Oatley, R. Langridge, and T. E. Ferrin. 1982. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161: 269-288.
27. Lang, P. T., S. R. Brozell, S. Mukherjee, E. F. Pettersen, E. C. Meng, V. Thomas, R. C. Rizzo, D. A. Case, T. L. James, and I. D. Kuntz. 2009. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 15: 1219-1230.
28. Moustakas, D. T., P. T. Lang, S. Pegg, E. Pettersen, I. D. Kuntz, N. Brooijmans, and R. C. Rizzo. 2006. Development and validation of a modular, extensible docking program: DOCK 5. J. Comput. Aided Mol. Des. 20: 601-619.
29. Baker, N. A., D. Sept, S. Joseph, M. J. Holst, and J. A. McCammon. 2001. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98: 10037-10041.
30. Minond, D., M. Cudic, N. Bionda, M. Giulianotti, L. Maida, R. A. Houghten, and G. B. Fields. 2012. Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates. J. Biol. Chem. 287: 36473-36487.
31. Lee, Y. W., D. H. Kim, S. J. Jeon, S. J. Park, J. M. Kim, J. M. Jung, H. E. Lee, S. G. Bae, H. K. Oh, K. H. Son, and J. H. Ryu. 2013. Neuroprotective effects of salvianolic acid B on an Aβ25-35 peptide-induced mouse model of Alzheimer's disease [Published erratum appears in 2013 Eur. J. Pharmacol. 714: 345]. Eur. J. Pharmacol. 704: 70-77.
32. Triguero, D., J. Buciak, and W. M. Pardridge. 1990. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54: 1882-1888.
33. Gutierrez, E. G., W. A. Banks, and A. J. Kastin. 1993. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 47: 169-176.
34. Solan, P. D., K. E. Dunsmore, A. G. Denenberg, K. Odoms, B. Zingarelli, and H. R. Wong. 2012. A novel role for matrix metalloproteinase-8 in sepsis. Crit. Care Med. 40: 379-387.
35. Gao, H. M., H. Zhou, and J. S. Hong. 2012. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol. Sci. 33: 295-303.
36. Kaminska, B. 2005. MAPK signalling pathways as molecular targets for antiinflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754: 253-262.
37. Kaminska, B., A. Gozdz, M. Zawadzka, A. Ellert-Miklaszewska, and M. Lipko. 2009. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat. Rec. (Hoboken) 292: 1902-1913.
38. Smale, S. T. 2010. Selective transcription in response to an inflammatory stimulus. Cell 140: 833-844.
39. Bedard, K., and K. H. Krause. 2007. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87: 245-313.
40. Ito, D., K. Tanaka, S. Suzuki, T. Dembo, and Y. Fukuuchi. 2001. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 32: 1208-1215.
41. Van Lint, P., and C. Libert. 2006. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 17: 217-223.
42. Vandenbroucke, R. E., E. Dejonckheere, P. Van Lint, D. Demeestere, E. Van Wonterghem, I. Vanlaere, L. Puimège, F. Van Hauwermeiren, R. De Rycke, C. Mc Guire, et al. 2012. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J. Neurosci. 32: 9805-9816.
43. Glass, C. K., K. Saijo, B. Winner, M. C. Marchetto, and F. H. Gage. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
44. Graeber, M. B., and W. J. Streit. 2010. Microglia: biology and pathology. Acta Neuropathol. 119: 89-105.
45. McGeer, P. L., and E. G. McGeer. 2013. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 126: 479-497.
46. Roberts, D. J., C. N. Jenne, C. Léger, A. H. Kramer, C. N. Gallagher, S. Todd, I. F. Parney, C. J. Doig, V. W. Yong, P. Kubes, and D. A. Zygun. 2013. A prospective evaluation of the temporal matrix metalloproteinase response after severe traumatic brain injury in humans. J. Neurotrauma 30: 1717-1726.
47. Chen, Z., W. Jalabi, K. B. Shpargel, K. T. Farabaugh, R. Dutta, X. Yin, G. J. Kidd, C. C. Bergmann, S. A. Stohlman, and B. D. Trapp. 2012. Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J. Neurosci. 32: 11706-11715.
48. Jeong, H. K., I. Jou, and E. H. Joe. 2010. Systemic LPS administration induces brain inflammation but not dopaminergic neuronal death in the substantia nigra. Exp. Mol. Med. 42: 823-832.
49. Ji, K. A., M. S. Yang, H. K. Jeong, K. J. Min, S. H. Kang, I. Jou, and E. H. Joe. 2007. Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain. Glia 55: 1577-1588.
50. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a doubleedged sword. Nat. Rev. Immunol. 3: 745-756.
51. McCoy, M. K., and M. G. Tansey. 2008. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 5: 45.
52. DasGupta, S., P. R. Murumkar, R. Giridhar, and M. R. Yadav. 2009. Current perspective of TACE inhibitors: a review. Bioorg. Med. Chem. 17: 444-459.
53. Moss, M. L., L. Sklair-Tavron, and R. Nudelman. 2008. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 4: 300-309.
54. Harms, A. S., J. K. Lee, T. A. Nguyen, J. Chang, K. M. Ruhn, I. Treviño, and M. G. Tansey. 2012. Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 60: 189-202.
55. Sriram, K., and J. P. O'Callaghan. 2007. Divergent roles for tumor necrosis factor-α in the brain. J. Neuroimmune Pharmacol. 2: 140-153.
56. Lauhio, A., J. Hästbacka, V. Pettilä, T. Tervahartiala, S. Karlsson, T. Varpula, M. Varpula, E. Ruokonen, T. Sorsa, and E. Kolho. 2011. Serum MMP-8,-9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol. Res. 64: 590-594.